M. van den Heuvel

Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R

Andrea Riccardo Filippi, Jair Bar, Christos Chouaid et al. · ESMO Open · 2024 · 50 citations · Full text

Medicine, Oncology, Radiation Oncology +14

Early body weight loss during concurrent chemo‐radiotherapy for non‐small cell lung cancer

Céline M. H. Op den Kamp, Dirk K.M. De Ruysscher, M. van den Heuvel et al. · Journal of Cachexia Sarcopenia and Muscle · 2014 · 30 citations · Full text

Medicine, Oncology, Radiation Oncology +16

1258MO Low dose versus standard dose pembrolizumab for treatment of stage IV stage non-small cell lung carcinoma: Results of the pre-planned interim analysis of the NVALT-30 clinical trial

M. van den Heuvel, Vincent van der Noort, Rob ter Heine · Annals of Oncology · 2024 · 23 citations · Full text

Medicine, Oncology, Pharmacology +16